Mutation in the progranulin (GRN) gene is just one of several hereditary factors that can cause frontotemporal dementia, a rare and rapidly progressive neurodegenerative disease.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
The current COO will assume leadership of the neuro-focused pharma firm while the company board investigates questions on Leen Kawas’s doctoral research.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
PPD’s patient access business unit AES will support clinical trial enrollment of participants in the Synexus HealthyMinds Registry, which aims to register 30,000 adults for a five-year study.
Previous setbacks in Alzheimer’s disease research for disease-modifying treatments have set the stage for a pipeline of new medicines now moving into clinical trials, according to a recent PhRMA report.
Synexus is looking to register 30,000 adults for a five-year study with the goal of identifying potential prevention methods and possible treatments for Alzheimer’s disease and other dementias.
